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CORRESPONDENCE
Reply to comment of “ERK and p38MAPK combine to
improve survival in patients with BRAF mutant colorectal
cancer”
British Journal of Cancer (2018) 119:909; https://doi.org/10.1038/
s41416-018-0275-7
Sir,
We are grateful for the comments of Uzunparmak and Sahin
regarding our paper on ERK and p38MAPK as prognostic markers
for patients with BRAF mutations.1
It is well-recognised CpG Island methylator phenotype (CIMP) is
a major cause of microsatellite instability in colorectal cancer due
to methylation of MLH-1 and that this is frequently coupled with
BRAF mutations. Unfortunately, we do not have CIMP analysis in
the present study cohort and therefore are unable to comment on
how this affects both Microsatallite instability (MSI) (measured
using mismatch repair deﬁciency (dMMR) as a surrogate in this
paper) and BRAF mutations within this cohort.
The authors suggest that the level of dMMR with BRAF
mutations at 16% in our cohort was low compared with other
studies and that in patients with sporadic dMMR, MLH-1
methylation or expression loss account for approximately 60%
of patients that harbour BRAF mutations.2 However, in the present
study dMMR was examined across the four common MMR
proteins (MLH-1, PMS-2, MSH-2 and MSH-6) and not just MLH-1.
If only MLH-1 was examined, then approximately 30% of patients
had BRAF mutations. In addition, the present cohort was not
tested for Lynch syndrome since there was no available germline
DNA. Lynch syndrome although associated with dMMR it is not
usually associated with BRAF mutation. Therefore, if some of the
present cohort had Lynch syndrome this may have also diluted
out the proportion of sporadic dMMR patients that had BRAF
mutations. Irrespective, we will look to better characterise the
present cohort in the future.
Although the pERK/p38MAPK score appeared to be most
effective when restricted to stage III MMR competent patients,
when all BRAF mutant patients were considered the pERK/
p38MAPK score was still associated with poorer survival indepen-
dent of TNM-stage suggesting a wider applicability in patients.
Clearly, the present work is required be conﬁrmed in other
cohorts, as external validation is key to any prognostic score being
taken forward. However, the simplicity of the present approach is
that in BRAF mutant patients it builds on MMR testing and
stratiﬁes the patients according to recognised signal transduction
pathways.
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